PGENHealthcare · BiotechnologyThe 3 Wall Street analysts covering Precigen, Inc. hold a median 12-month price target of $15 — +137.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Precigen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (100): Analysts have, on balance, been raising their forecasts.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +137.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $14 → $18 |
| 3 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $14 |
| 28 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 May 2026 | HC Wainwright & Co. | Maintains | Buy | $11 → $14 |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 14 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2025 | JP Morgan | Upgrade | Neutral | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 15 May 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGEN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 8% of US stocks
Cheaper than 2% of US stocks
Cheaper than 95% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 98% of US stocks
Higher than 92% of US stocks
Higher than 3% of US stocks
Higher than 2% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Precigen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published an analysis questioning whether Precigen, Inc. (PGEN) has the characteristics to be a strong pick for momentum investors.
Why it matters — PGEN watchers would care because the analysis evaluates the company's momentum profile, which could influence investor perception and stock activity.
Seeking Alpha reports that Precigen, Inc. surged 266% following FDA approval of PAPZIMEOS, which is now the company's sole revenue driver with $53.1 million in Q2 revenue and low cost of goods sold. The company now trades at a premium valuation near $2.24 billion, while its pipeline faces stiff competition and weaker efficacy than rival treatments.
Why it matters — PGEN watchers would care because the analysis questions whether the company's higher valuation is justified given its reliance on a single approved product and competitive pipeline pressures.
Precigen, Inc. was upgraded to a Strong Buy rating, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis. The company achieved profitability in Q2 2026, with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity, while potential European approval and AdenoVerse platform expansion, including PRGN-2009, could open new opportunities.
Why it matters — PGEN watchers would care because the item highlights a profitability milestone, strong PAPZIMEOS revenue growth, seven years of U.S. market exclusivity, and potential European approval and platform expansion that could unlock significant new market opportunities.
Precigen, Inc. held its Q2 2026 earnings call and released the transcript of the event on Seeking Alpha.
Why it matters — A PGEN watcher would care because the earnings call transcript provides management's discussion of the company's quarterly financial results and operational progress.
Precigen reported a sharp increase in second-quarter revenue driven by the launch of PAPZIMEOS. The company reached quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis.
Why it matters — For PGEN watchers, the revenue surge and early return to profitability following PAPZIMEOS's approval point to commercial traction for the company's first marketed therapy.
The 3 Wall Street analysts covering Precigen, Inc. have a median 12-month price target of $15, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Precigen, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Precigen, Inc. 80 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Precigen, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (100 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +137.7% from the last close, and Ticker Nerd's factor model ranks Precigen, Inc. 80 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Precigen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.
Precigen, Inc. returned +229.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice". Zacks Investment Research published an analysis questioning whether Precigen, Inc. (PGEN) has the characteristics to be a strong pick for momentum investors.
Precigen Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company operates through two primary business segments: Biopharmaceuticals and Exemplar. Precigen's therapeutic platforms include the AdenoVerse platform, which leverages a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and UltraCAR-T, which provides chimeric antigen receptor T cell therapies for cancer patients. A significant milestone in the company's development includes FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), the first and only approved therapy for treating adults with recurrent respiratory papillomatosis, a rare and debilitating chronic respiratory disease. Founded in 1998 and headquartered in Germantown, Maryland, Precigen represents an emerging player in the precision medicine sector, combining innovative gene therapy approaches with immunotherapy strategies.
CEO Dr. Helen Sabzevari MPH, Ph.D. · 160 employees · United States · https://precigen.com